Alcon/$ALC

13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1Y5YMAX

About Alcon

Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.

Ticker

$ALC

Primary listing

NYSE

Industry

Health Care Equipment & Supplies

Headquarters

Geneva, Switzerland

Employees

25,000

ISIN

CH0432492467

Alcon Metrics

BasicAdvanced
$44B
39.69
$2.25
0.70
$0.18
0.20%

What the Analysts think about Alcon

Analyst ratings (Buy, Hold, Sell) for Alcon stock.

Bulls say / Bears say

Alcon's new dry-eye drug, Tryptyr, received FDA approval in May 2025, potentially expanding its market share in the dry eye treatment sector. (reuters.com)
Analysts have set an average 12-month price target of $106.13 for Alcon, indicating a potential upside of approximately 20.25%. (marketbeat.com)
Alcon's strategic investments in fast-growing market segments, such as the PRECISION1 family and DAILIES TOTAL1 for astigmatism, have led to significant market share gains in the contact lens category. (nasdaq.com)
Alcon is experiencing inflationary pressures in electronic components, freight, labor, resins, and plastics, which are impacting the company's margins. (nasdaq.com)
The ophthalmology industry is highly competitive, with Alcon facing intense competition in both surgical and vision care businesses, including from providers of alternative medical therapies. (nasdaq.com)
Alcon's P/E ratio of 39.08 is higher than the market average of about 24.88, suggesting the stock may be overvalued compared to the broader market. (marketbeat.com)
Data summarised monthly by Lightyear AI. Last updated on 2 Jul 2025.

Alcon Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Alcon Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ALC

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs